BioSpace News Archive

Drug Development

Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications

Innovent Biologics, Inc. announces that results of a Phase 2 clinical trial of mazdutide, a glucagon-like peptide-1 receptor and glucagon receptor dual agonist, in Chinese patients with overweight or obesity were published in Nature Communications.

December 17, 2023
·
9 min read
Business

InnoCare Appoints Xin Fu as Chief Financial Officer

InnoCare Pharma, a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced that the Company appointed Mr. Xin Fu, who has extensive finance-related experience, as the Chief Financial Officer.

December 17, 2023
·
2 min read
Drug Development

InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-332 Meet Primary Endpoint in Patients with Atomic Dermatitis

InnoCare Pharma announced that phase II clinical study results of novel TYK2 inhibitor ICP-332 met primary endpoint in adult patients with moderate-to-severe atopic dermatitis.

December 17, 2023
·
3 min read
First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM

YolTech Therapeutics announced that the first patient has been dosed with YOLT-201, the company’s first in vivo genome editing candidate being developed as a single dose, potentially curative therapy for hereditary transthyretin amyloidosis with cardiomyopathy.

December 17, 2023
·
3 min read
Policy

EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children

Astellas Pharma Inc. contributed to the development of a pediatric formulation to treat schistosomiasis as a member of the Pediatric Praziquantel Consortium.

December 17, 2023
·
8 min read
FDA

GC Biopharma Announces US FDA Approval for ALYGLO™ (Immune Globulin Intravenous, Human-stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)

GC Biopharma Corp announces that the US Food and Drug Administration has approved ALYGLO 10% Liquid, formerly referred to as “GC5107,” for the treatment of adult patients aged 17 years and older with primary humoral immunodeficiency.

December 17, 2023
·
9 min read